Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345861 | 0.84 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2CYP2D6 | |
| SCHEMBL24488616 | 0.83 | AAK1 (0.33) | AAK1HDAC6HDAC1HDAC2CYP2D6 | |
| SCHEMBL8335981 | 0.83 | AAK1 (0.33) | AAK1HDAC6HDAC1HDAC2CYP2D6 | |
| SCHEMBL4794923 | 0.80 | AAK1 (0.34) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL18885732 | 0.80 | AAK1 (0.34) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL28449893 | 0.80 | AAK1 (0.34) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL15766040 | 0.80 | HDAC6 (0.37) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL27831663 | 0.80 | MMP13 (0.34) | AAK1HDAC6HDAC1HDAC2DGAT1 | |
| SCHEMBL21964901 | 0.80 | CA1 (0.35) | AAK1HDAC6HDAC1HDAC2CYP2D6 | |
| SCHEMBL5196404 | 0.79 | AAK1 (0.32) | AAK1HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875456-A | Preparation method of low-temperature-resistant coating for natural gas metal pipeline | 廊坊市泰锐通石油燃气管道工程有限公司 | 2025-04-25 | — | — | CN | claimed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4219478-B1 | METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| CN-119875456-A | Preparation method of low-temperature-resistant coating for natural gas metal pipeline | 廊坊市泰锐通石油燃气管道工程有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-118994283-A | Beta-D-galactopyranose compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-11-22 | — | — | CN | disclosed |
| CN-118715226-A | Compounds and uses thereof | 上海岸阔医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230312483-A1 | Amino Pyrimidine Derivatives | NOVARTIS AG (CH) | 2023-10-05 | — | — | US | disclosed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050038056-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005007633-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1212301-A1 | ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016107-A1 | ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0706532-B1 | Peptides having endothelin antagonictic activity,their preparation and pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5888972-A | ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0706532-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995000537-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
| US-4007184-A | BACTERICIDE, ANIMAL GROWTH REGULATOR | PFIZER INC. (US) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038056-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | AAK1 4646/4885HDAC6 1962/4885HDAC1 855/4885 |
| US-20230312483-A1 | Amino Pyrimidine Derivatives | BTK, LCK, JAK1 | AAK1 325/4885HDAC6 2387/4885HDAC1 4181/4885 |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | AAK1 3890/4885HDAC6 1736/4885HDAC1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.